A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

NCT03875079 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: RO6874281
DRUG: Pembrolizumab

Sponsor

Hoffmann-La Roche